Exclusive: A couple paid more than $800000 for a gene-editing therapy for their daughter. She died, and it wasn't made public

An investigation by Science and Retraction Watch has exposed a hidden clinical trial tragedy involving a 6-year-old girl in Shanghai. The child, who suffered from a rare genetic mutation, passed away seven days after receiving an experimental gene-editing therapy at Xinhua Hospital. Her parents had contributed over $800,000 of their own savings to fund the study.

While researchers published preclinical work related to this project in Nature earlier this year, they omitted any mention of the human trial or the tragic outcome. The published paper makes no reference to the financial contributions made by the family, and the clinical trial registration has remained inactive for more than a year. Experts in genetics and bioethics are now raising serious questions about the safety data and the oversight of the project.

The medical team at the Songjiang Research Institute reportedly operated under a regulatory provision that bypassed national approval requirements. This lack of transparency has prompted calls for a full review of the data and a possible retraction of the published research. The girl's parents are speaking out now because they feel the institutions involved failed to maintain necessary safety standards and accountability.

Independent researchers who reviewed the study details noted that the risks were likely downplayed and that the team proceeded despite questionable odds of success. As the scientific community examines the published paper, the case highlights persistent concerns regarding the culture of secrecy in certain institutional research settings. This situation raises difficult questions about how experimental medical procedures are vetted when they bypass standard regulatory review boards.